GeneReach Biotechnology (4171) — Cash Flow Quality Index
GeneReach Biotechnology (4171) has a Cash Flow Quality Index of 4.33x as of December 2025. Operating cash flow of NT$12.05 Million exceeds net income of NT$2.79 Million, indicating high earnings quality where cash backs reported profits. Also explore 4171 total asset value for the complete picture of this company's asset base.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
GeneReach Biotechnology Cash Flow Quality Index (2018–2022)
Historical Cash Flow Quality Index for GeneReach Biotechnology across 5 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check GeneReach Biotechnology (4171) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for GeneReach Biotechnology (2018–2022)
Year-by-year earnings quality comparison for GeneReach Biotechnology. For live market cap and the full company financial profile, see GeneReach Biotechnology (4171) market capitalisation.
| Year | Quality Index | Operating CF (TWD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2022 | 1.62x | NT$357.63 Million | NT$221.34 Million | ▲ +117.3% |
| 2021 | 0.74x | NT$348.99 Million | NT$469.37 Million | ▲ +48.4% |
| 2020 | 0.50x | NT$169.82 Million | NT$338.94 Million | ▲ +445.5% |
| 2019 | -0.15x | NT$-11.19 Million | NT$77.18 Million | ▼ -172.1% |
| 2018 | 0.20x | NT$5.74 Million | NT$28.57 Million | — |